180 Wealth Advisors LLC Grows Stake in Illumina, Inc. $ILMN

180 Wealth Advisors LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 8.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,164 shares of the life sciences company’s stock after purchasing an additional 2,717 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Illumina were worth $3,355,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Rise Advisors LLC raised its position in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. purchased a new position in Illumina in the second quarter valued at about $41,000. Golden State Wealth Management LLC raised its position in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 292 shares during the period. Caitong International Asset Management Co. Ltd raised its position in Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the period. Finally, WPG Advisers LLC purchased a new position in Illumina in the first quarter valued at about $58,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Barclays raised their price objective on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Evercore ISI dropped their target price on Illumina from $135.00 to $132.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Morgan Stanley lifted their target price on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Canaccord Genuity Group lifted their target price on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Finally, Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $115.25.

Illumina Trading Up 2.8%

NASDAQ:ILMN opened at $99.97 on Friday. The company has a market cap of $15.37 billion, a PE ratio of 12.65, a P/E/G ratio of 2.40 and a beta of 1.40. The business’s 50 day moving average is $98.17 and its two-hundred day moving average is $91.30. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $0.36 EPS. The business’s quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.